---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-046076"
form_type: "8-K"
ticker: "IRIX"
cik: "0001006045"
company_name: "IRIDEX CORP"
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T03:34:03.614806+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Iridex posts Q4 2024 revenue $12.7M, achieves positive adjusted EBITDA; net loss narrows to $0.8M

## Summary
- Q4 revenue $12.7M vs $12.5M YoY; adjusted EBITDA positive $0.4M vs ($2.0M) loss prior year.
- Net loss improved to $0.8M ($0.05/share) from $3.0M ($0.18/share); operating expenses down 24% to $6.1M.
- Cyclo G6 product family revenue $3.3M (+9% YoY); retina product revenue $7.3M (-3%).
- Cash $2.4M at year-end; subsequent $10M strategic investment from Novel Innovations at $2.00/share.
- Guidance: expects cash flow breakeven and positive adjusted EBITDA in 2025 on FY revenue consistent with 2024.

## SEC filing metadata
- accession: 0000950170-25-046076
- form_type: 8-K
- ticker: IRIX
- cik: 0001006045
- company_name: IRIDEX CORP
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006045/000095017025046076/0000950170-25-046076-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006045/000095017025046076/irix-20250327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-046076
- JSON: https://secwatch.observer/filing/0000950170-25-046076.json
- Plain text: https://secwatch.observer/filing/0000950170-25-046076.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.